Singular Genomics Systems, Inc. (NASDAQ:OMIC) Short Interest Update

Singular Genomics Systems, Inc. (NASDAQ:OMIC) was the recipient of a significant decline in short interest during the month of July. As of July 15th, there was short interest totalling 12,400 shares, a decline of 17.9% from the June 30th total of 15,100 shares. Based on an average daily volume of 5,600 shares, the short-interest ratio is presently 2.2 days. Approximately 0.9% of the shares of the company are sold short.

Singular Genomics Systems Stock Performance

Shares of Singular Genomics Systems stock traded up $0.32 on Tuesday, reaching $8.10. 1,134 shares of the company were exchanged, compared to its average volume of 4,742. The firm has a market cap of $20.17 million, a price-to-earnings ratio of -0.20 and a beta of 1.35. Singular Genomics Systems has a 1-year low of $7.21 and a 1-year high of $24.60. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.54 and a current ratio of 10.35. The company’s 50-day moving average is $9.46 and its two-hundred day moving average is $12.65.

Singular Genomics Systems (NASDAQ:OMIC) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($10.20) EPS for the quarter. The company had revenue of $0.44 million for the quarter, compared to the consensus estimate of $0.50 million. Singular Genomics Systems had a negative return on equity of 51.10% and a negative net margin of 3,863.90%.

Institutional Trading of Singular Genomics Systems

An institutional investor recently raised its position in Singular Genomics Systems stock. Weil Company Inc. grew its holdings in shares of Singular Genomics Systems, Inc. (NASDAQ:OMIC) by 16.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 138,202 shares of the company’s stock after buying an additional 20,000 shares during the period. Weil Company Inc. owned 0.19% of Singular Genomics Systems worth $64,000 as of its most recent filing with the Securities and Exchange Commission. 65.80% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group reduced their price target on shares of Singular Genomics Systems from $22.50 to $6.50 and set a “neutral” rating on the stock in a research report on Tuesday, July 9th.

Singular Genomics Systems Company Profile

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.